Scholay

学术搜索 · AI 审稿 · LaTeX 协作

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

作者:Usama Gergis, Aaron J. Martin, A. Vogel, Jeff Smith, Andreas K. Klein, Ran Reshef, Rajneesh Nath, Adam J. Olszewski, Alan F. List, Alex F. Herrera, Michael D. Jain · 发表于:Blood · 年份:2024 · DOI:10.1182/blood-2024-210499 · 被引用次数:2 · 研究领域:CAR-T cell therapy research、Viral Infectious Diseases and Gene Expression in Insects

Background: The efficacy of CAR T cell products has been limited by host immune rejection. PBCAR19B or “Stealth Cell” is a of cluster of differentiation (CD)19-directed allogeneic CAR T-cell therapy designed to evade immune rejection in order to extend target engagement and improve clinical efficacy. PBCAR19B is derived from healthy donor T cells in which a stealth construct is inserted into the T cell receptor alpha constant (TRAC) gene locus via a TRAC-specific ARCUS nuclease. In addition to the anti-CD19 CAR gene, the stealth construct carries a microRNA that suppresses expression of beta-2 microglobulin (B2M), a component of Class 1 major histocompatibility complex (MHC) molecules found on the cell surface. Reducing or knocking down Class 1 expression on allogeneic CAR T cells has been shown to reduce CAR T cell killing by cytotoxic T cells. The stealth construct also carries a HLA-E gene intended to prevent rejection of CAR T cells by NK cells that can be stimulated as a result of reduced MHC expression on the cell surface. Together, these key features position PBCAR19B as a potential off-the-shelf-treatment with improved persistence in CD19-related indications. Methods: PBCAR19B was administered as a single infusion to adult subjects with measurable CD19+ R/R NHL. Prior hematopoietic cell transplant or treatment with a CD19-directed autologous CAR T therapy was permitted. Two lymphodepletion (LD) regimens were tested, including standard (sLD), fludarabine 30 mg/m2/day ×...